Magnesium Treatment in Hypoparathyroidism

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Vallo Volke, University of Tartu

ClinicalTrials.gov Identifier:

NCT00824226

First received: January 15, 2009

Last updated: August 26, 2011

Last verified: August 2011

History of Changes

Purpose

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Condition	Intervention
Hypoparathyroidism	Dietary Supplement: magnesium


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Resource links provided by NLM:

MedlinePlus related topics: Calcium

Drug Information available for: Magnesium

Genetic and Rare Diseases Information Center resources: Hypoparathyroidism

U.S. FDA Resources

Further study details as provided by Vallo Volke, University of Tartu:

Primary Outcome Measures:

Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ]

Secondary Outcome Measures:

Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ]


Enrollment:	10
Study Start Date:	January 2009
Study Completion Date:	August 2011
Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)

Intervention Details:

magnesium 350 mg tablets once a day for 3 weeks

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

primary or secondary hypoparathyroidism
treatment with calcium plus vitamin D analogue
ionized calcium 1,0-1,29 mmol/L
magnesium level 0,7-1,05 mmol/L
TSH 0.1- 10 imU/L

Exclusion Criteria:

any other disease known to influence plasma Ca level
pregnancy
creatinine > 150 microM/L
patient has used supplementary magnesium within 2 previous months

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824226

Locations


Estonia
Tartu University Hospital
Tartu, Estonia, 50406

Sponsors and Collaborators

University of Tartu

Investigators


Principal Investigator:	Vallo Volke, MD, PhD	University of Tartu, Institute of Physiology

More Information


Responsible Party:	Vallo Volke, Dr., University of Tartu
ClinicalTrials.gov Identifier:	NCT00824226 History of Changes
Other Study ID Numbers:	UT296
Study First Received:	January 15, 2009
Last Updated:	August 26, 2011

Keywords provided by Vallo Volke, University of Tartu:


primary hypoparathyroidism secondary hypoparathyroidism magnesium

Additional relevant MeSH terms:


Hypoparathyroidism Parathyroid Diseases Endocrine System Diseases

ClinicalTrials.gov processed this record on July 25, 2017

To Top